Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21493197 | 0.84 | BACE1 (0.34) | USP14BACE1ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL8126037 | 0.83 | ALDH1A1 (0.46) | ALDH1A1TSHRNPC1RAB9AL3MBTL1 | |
| SCHEMBL13582079 | 0.81 | ESR1 (0.44) | USP14BACE1ALDH1A1KMT2AGAA | |
| SCHEMBL13582083 | 0.81 | ESR1 (0.44) | USP14BACE1ALDH1A1KMT2AGAA | |
| SCHEMBL30206765 | 0.81 | CDK1 (0.49) | BACE1TRIM24TYRTRIM33 | |
| SCHEMBL19640063 | 0.81 | CDK1 (0.49) | BACE1TRIM24TYRTRIM33 | |
| SCHEMBL17508765 | 0.81 | USP14 (0.34) | USP14BACE1L3MBTL1KMT2ATDP1 | |
| SCHEMBL13581970 | 0.81 | USP14 (0.35) | USP14BACE1 | |
| SCHEMBL13581966 | 0.81 | USP14 (0.35) | USP14BACE1 | |
| SCHEMBL30206825 | 0.80 | ERN1 (0.38) | USP14BACE1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344338-A | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for the treatment of lymphomas | 细胞基因公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2024-07-04 | — | — | US | disclosed |
| CN-113214220-B | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for the treatment of lymphomas | 细胞基因公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-111989322-B | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for the treatment of lymphomas | 细胞基因公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11945804-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4272737-A2 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | Celgene Corporation (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3784663-B1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | CELGENE CORP (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220306611-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2022-09-29 | — | — | US | disclosed |
| US-11358952-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-06-14 | — | — | US | disclosed |
| CN-113214220-A | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for treating lymphomas | 细胞基因公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3784663-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | Celgene Corporation (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-111989322-A | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for treating lymphomas | 细胞基因公司 | 2020-11-24 | — | — | CN | disclosed |
| US-20190322647-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945804-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith | AANAT, HTR2C, AADAT | USP14 3374/4885BACE1 921/4885ALDH1A1 96/4885 |
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AANAT, HTR2C, AADAT | USP14 3374/4885BACE1 921/4885ALDH1A1 96/4885 |
| US-20190322647-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AANAT, HTR2C, AADAT | USP14 3374/4885BACE1 921/4885ALDH1A1 96/4885 |
| US-11358952-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith | AANAT, HTR2C, AADAT | USP14 3374/4885BACE1 921/4885ALDH1A1 96/4885 |
| US-20220306611-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AANAT, HTR2C, AADAT | USP14 3374/4885BACE1 921/4885ALDH1A1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.